Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 1.10 M

Inozyme Pharma, Inc. Gross Profit is USD 1.10 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 211.84% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Inozyme Pharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -988.00 K, a 13.79% change year over year.
Inozyme Pharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.15 M, a -132.93% change year over year.
Inozyme Pharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -492.00 K, a 0.00% change year over year.
Inozyme Pharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO	Dr. Douglas A. Treco Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Summer Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years